|
US7563874B2
(en)
*
|
1998-08-31 |
2009-07-21 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
IL147765A0
(en)
*
|
1999-07-29 |
2002-08-14 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
|
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
|
ES2531551T3
(es)
*
|
2000-04-17 |
2015-03-17 |
Dyax Corp. |
Métodos para construir bibliotecas de presentación de paquetes genéticos para miembros de una familia diversa de péptido
|
|
ES2331646T3
(es)
|
2000-05-19 |
2010-01-12 |
Genentech, Inc. |
Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb.
|
|
DE60144063D1
(de)
|
2000-12-18 |
2011-03-31 |
Dyax Corp |
Gerichtete bibliotheken die genetisch verpackt sind
|
|
ITRM20010408A1
(it)
*
|
2001-07-10 |
2003-01-10 |
Univ Napoli Federico Ii |
Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
|
|
US20050037061A1
(en)
*
|
2001-07-25 |
2005-02-17 |
Saiko Hosokawa |
Remedies for mammary cancer
|
|
EP1539235A2
(en)
|
2002-07-01 |
2005-06-15 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to reg iv
|
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
US6987270B2
(en)
|
2003-05-07 |
2006-01-17 |
General Electric Company |
Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
|
|
EP1663171B9
(en)
|
2003-08-26 |
2009-08-19 |
SmithKline Beecham Corporation |
Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions
|
|
BRPI0416987A
(pt)
*
|
2003-11-28 |
2007-08-21 |
Mitra Medical Technology Ab |
direcionamento de antìgenos de erb
|
|
CN107811971B
(zh)
|
2004-05-03 |
2021-10-29 |
益普生生物制药公司 |
用于药物输送的脂质体
|
|
AU2005295072A1
(en)
|
2004-10-08 |
2006-04-20 |
Alza Corporation |
Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
|
|
PL1846030T3
(pl)
|
2005-01-21 |
2019-05-31 |
Genentech Inc |
Ustalone dawkowanie przeciwciał her
|
|
WO2007094754A2
(en)
*
|
2005-01-27 |
2007-08-23 |
The Regents Of The University Of Califordnia |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
GB0503546D0
(en)
*
|
2005-02-21 |
2005-03-30 |
Hellenic Pasteur Inst |
Antibody
|
|
UA95902C2
(ru)
|
2005-02-23 |
2011-09-26 |
Дженентек, Инк. |
Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
|
|
PT2511301T
(pt)
*
|
2006-08-04 |
2018-03-08 |
Medimmune Ltd |
Anticorpos humanos para erbb2
|
|
CA2672393C
(en)
*
|
2006-12-12 |
2014-11-18 |
Morphosys Ag |
Internalization
|
|
NZ578824A
(en)
|
2007-03-02 |
2012-03-30 |
Genentech Inc |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
|
EP2134749B1
(en)
*
|
2007-03-22 |
2013-11-06 |
The Regents of the University of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
WO2008141274A1
(en)
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Anti-alpha v immunoliposome composition, methods and uses
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
EP2592156B1
(en)
|
2007-06-08 |
2016-04-20 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
CA2697193C
(en)
|
2007-09-14 |
2017-06-06 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US9873957B2
(en)
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
|
DK2281078T3
(en)
|
2008-04-24 |
2015-02-02 |
Dyax Corp |
LIBRARIES OF RE-PACKAGES INCLUDING UNKNOWN HC-CDR1, -CDR2 AND -CDR3 AND UNKNOWN LC-CDR1, -CDR2 AND-CDR3 DESIGNS
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
US9000131B2
(en)
*
|
2008-07-31 |
2015-04-07 |
The Regents Of The University Of California |
Antibodies that neutralize botulinum neurotoxins
|
|
US8734795B2
(en)
|
2008-10-31 |
2014-05-27 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
|
MA33198B1
(fr)
|
2009-03-20 |
2012-04-02 |
Genentech Inc |
Anticorps anti-her di-spécifiques
|
|
JP5705836B2
(ja)
|
2009-05-29 |
2015-04-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
|
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
|
EP2542589A4
(en)
*
|
2010-03-04 |
2013-08-07 |
Symphogen As |
ANTIBODIES AND COMPOSITIONS ANTI-HER2
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
CN103154035B
(zh)
|
2010-05-27 |
2017-05-10 |
根马布股份公司 |
针对her2的单克隆抗体
|
|
JP6082344B2
(ja)
|
2010-05-27 |
2017-02-15 |
ゲンマブ エー／エス |
Ｈｅｒ２エピトープに対するモノクローナル抗体
|
|
AU2011279073B2
(en)
|
2010-07-16 |
2016-06-09 |
Adimab, Llc |
Antibody libraries
|
|
US9243057B2
(en)
|
2010-08-31 |
2016-01-26 |
The Regents Of The University Of California |
Antibodies for botulinum neurotoxins
|
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
|
CA2820245A1
(en)
|
2010-12-06 |
2012-06-14 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
|
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012112730A2
(en)
|
2011-02-15 |
2012-08-23 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
JP6177231B2
(ja)
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー／エス |
Ｈｅｒ２に対する二重特異性抗体
|
|
JP2014514314A
(ja)
|
2011-04-20 |
2014-06-19 |
ゲンマブ エー／エス |
Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
|
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
|
WO2013043864A1
(en)
*
|
2011-09-23 |
2013-03-28 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to endothelial targeting
|
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
|
WO2013081645A2
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
CN104220457A
(zh)
|
2012-03-27 |
2014-12-17 |
霍夫曼-拉罗奇有限公司 |
涉及her3抑制剂的诊断和治疗
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
WO2013192294A1
(en)
*
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
RU2692773C2
(ru)
|
2012-11-30 |
2019-06-27 |
Ф.Хоффманн-Ля Рош Аг |
Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
|
|
US9913901B2
(en)
|
2012-12-03 |
2018-03-13 |
Merrimack Pharmaceuticals, Inc. |
Combination therapy for treating HER2-positive cancers
|
|
US10519247B2
(en)
*
|
2013-11-01 |
2019-12-31 |
Board Of Regents,The University Of Texas System |
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
|
|
US10160812B2
(en)
|
2014-04-11 |
2018-12-25 |
Medimmune, Llc |
Bispecific HER2 antibodies
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗ｈｅｒ２表位之單株抗體及其使用之方法
|
|
US20160045596A1
(en)
|
2014-08-05 |
2016-02-18 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
CN107405382A
(zh)
|
2015-02-06 |
2017-11-28 |
加利福尼亚大学董事会 |
用于改善认知的方法和组合物
|
|
US10336816B2
(en)
*
|
2015-02-24 |
2019-07-02 |
Academia Sinica |
Phage-displayed single-chain variable fragment library
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
ES2848118T3
(es)
|
2015-08-20 |
2021-08-05 |
Ipsen Biopharm Ltd |
Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer
|
|
TWI778942B
(zh)
|
2015-08-21 |
2022-10-01 |
英商益普生生物製藥有限公司 |
使用包含微脂伊立替康（ｉｒｉｎｏｔｅｃａｎ）及奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）之組合療法治療轉移性胰臟癌的方法
|
|
RU2732567C2
(ru)
|
2015-10-16 |
2020-09-21 |
Ипсен Биофарм Лтд. |
Стабилизированные фармацевтические композиции камптотецина
|
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
|
TWI758267B
(zh)
|
2015-12-14 |
2022-03-21 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
|
BR112019007844A2
(pt)
|
2016-11-02 |
2019-07-16 |
Ipsen Biopharm Ltd |
tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
MX2020006155A
(es)
|
2017-12-12 |
2020-08-13 |
Macrogenics Inc |
Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
|
|
SG11202007572VA
(en)
|
2018-02-15 |
2020-09-29 |
Macrogenics Inc |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
|
WO2020163306A1
(en)
|
2019-02-04 |
2020-08-13 |
The Regents Of The University Of California |
Exercise-induced circulatory factors for amelioration of cognitive, neurological, and regenerative dysfunction during aging
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
WO2024092238A1
(en)
|
2022-10-28 |
2024-05-02 |
Unity Biotechnology, Inc. |
Klotho polypeptide or polynucleotide for improving cognition
|